AI assistant
Sending…
Phathom Pharmaceuticals, Inc. — Director's Dealing 2023
Nov 3, 2023
32407_dirs_2023-11-03_935770bd-ebb3-4368-bb81-cc37236d79ea.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2023-11-01
Reporting Person: Curran Terrie (Director, President and Chief Executive)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-11-01 | Common Stock | A | 37500 | $0.00 | Acquired | 427171 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 3579.61 | Indirect |
Footnotes
F1: Represents shares earned with respect to performance stock unit awards granted on July 1, 2020 and January 19, 2023 that contained a performance-vesting requirement that was satisfied on November 1, 2023.
More from Phathom Pharmaceuticals, Inc.
Regulatory Filings
2026
May 21
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Annual Report
2026
Apr 7
Proxy Solicitation & Information Statement
2026
Apr 7
Regulatory Filings
2026
Mar 27
Director's Dealing
2026
Mar 3
Annual Report
2026
Feb 26
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 12